Search

Your search keyword '"Hilton, Holly"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Hilton, Holly" Remove constraint Author: "Hilton, Holly"
136 results on '"Hilton, Holly"'

Search Results

3. Supplementary Table 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

4. Supplementary Table 1 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

5. Supplementary Table 2 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

6. Supplementary Figure Legends and Table Legends and Methods from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

7. Supplementary Figure 1 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

8. Supplementary Figure 3 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

9. Supplementary Figure 2 from RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

10. Data from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

11. Supplementary Methods and Materials from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

12. Supplementary Figure 2 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

13. Supplementary Figure 1 from Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

14. Transportation and Land Use

19. Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Brutonʼs Tyrosine Kinase

21. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

23. Speciation and domestication in maize and its wild relatives: evidence from the globulin-I gene

25. DNA sequence variation at the period locus reveals the history of species and speciation events in the Drosophila virilis group

27. Evaluation of a developmental hierarchy for breast cancer cells to assess risk-based patient selection for targeted treatment

28. Persistence of circulating endothelial microparticles in COPD despite smoking cessation

29. Persistence of Smoking-Induced Dysregulation of MiRNA Expression in the Small Airway Epithelium Despite Smoking Cessation

31. Translational medicine and biomarkers: transfer of knowledge between pre-clinical and clinical research is necessary to deliver effective medicines to patients

32. Intraflagellar Transport Gene Expression Associated with Short Cilia in Smoking and COPD

33. RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

34. Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity

35. "Memory Of Smoking": Persistent Dysregulation Of Expression Of A Subset Of Smoking-Related Genes In The Small Airway Epithelium 3 Months Following Smoking Cessation

36. Abstract 4827: Humanized hepsin neutralizing antibody RO5486055 inhibits tumor growth and leads to accumulation of hepsin substrate laminin-332

37. RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

38. Whole Blood Gene Expression And Serum Biomarker Profiling In A COPD Cohort Identifies Markers Related To Neutrophilic Inflammation, Wound Healing And Altered B Cell Signaling

41. Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

42. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

44. Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in Rat

46. Computational dissection of tissue contamination for identification of colon cancer‐specific expression profiles

49. The mRNA level of Charcot-Leyden crystal protein/galectin-10 is a marker for CRTH2 activation in human whole blood in vitro.

Catalog

Books, media, physical & digital resources